Eribulin Advanz Pharma 0.44 mg/ml inj. sol. i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eribulin advanz pharma 0.44 mg/ml inj. sol. i.v. vial

advanz pharma ltd. - eribulin mesylate 0,5 mg - eq. eribulin 0,44 mg - solution for injection - eribulin

Ocaliva European Union - English - EMA (European Medicines Agency)

ocaliva

advanz pharma limited - obeticholic acid - liver cirrhosis, biliary - bile and liver therapy - ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca or as monotherapy in adults unable to tolerate udca.